Should antenatal corticosteroids be administered during the third trimester to prevent neonatal respiratory distress?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Should Corticosteroids Be Given in the Third Trimester to Prevent Neonatal Respiratory Distress?

Yes, but only if you are at high risk of delivering between 34+0 and 36+6 weeks within the next 7 days—give betamethasone 12 mg intramuscularly twice, 24 hours apart. Do not give corticosteroids if delivery before 37 weeks is unlikely, and avoid them entirely at or after 37 weeks even for planned cesarean delivery 1.

When to Give Corticosteroids in the Third Trimester

Late Preterm Period (34+0 to 36+6 weeks): RECOMMENDED

The Society for Maternal-Fetal Medicine provides Grade 1A evidence supporting corticosteroid administration during this window 1. You must meet these specific criteria:

  • Singleton pregnancy between 34+0 and 36+6 weeks
  • High risk of delivery within 7 days AND before 37 weeks
  • No previous course of antenatal corticosteroids

The landmark ALPS trial demonstrated clear benefits: corticosteroids reduced the need for respiratory support from 14.4% to 11.6% (RR 0.80) and severe respiratory morbidity from 12.1% to 8.1% (RR 0.67) 1. This translates to preventing respiratory complications in approximately 1 in 36 treated pregnancies.

Term Gestation (≥37 weeks): NOT RECOMMENDED

Do not give corticosteroids at term, even for planned cesarean delivery 2. The 2022 RCOG guidelines explicitly state that while corticosteroids may reduce NICU admission for respiratory morbidity, there is low certainty of benefit for respiratory distress syndrome or transient tachypnea, and they increase neonatal hypoglycemia risk 2. The baseline risk of respiratory distress at term is only ~5% and is typically mild and self-limited 2.

A 2024 randomized controlled trial from India found no benefit when betamethasone was given in the late preterm period—the primary outcome occurred in 4.9% with betamethasone versus 4.8% with placebo (RR 1.03) 3. This contradicts earlier evidence but represents the most recent high-quality data.

Critical Contraindications and Cautions

Absolute Contraindication: Pregestational Diabetes

Do not give late preterm corticosteroids to women with pregestational diabetes mellitus (Grade 1C) 1. These women were excluded from the ALPS trial, and their neonates face substantially higher hypoglycemia risk, which independently associates with developmental delays in preschool-aged children 1.

Avoid in Low-Risk Situations

Do not give corticosteroids if delivery before 37 weeks is unlikely (Grade 1B) 1. The potential harms—including neonatal hypoglycemia and uncertain long-term neurodevelopmental effects—outweigh benefits when preterm delivery is not imminent.

Dosing Regimen

When indicated, use betamethasone 12 mg intramuscularly, two doses 24 hours apart 1, 2. This is the regimen validated in the ALPS trial and endorsed by all major guidelines.

Alternative: Dexamethasone 6 mg intramuscularly every 12 hours for four doses, though betamethasone is preferred 4.

Special Populations

Multiple Gestations

Consider corticosteroids in select cases such as multiple gestations reduced to singleton on or after 14+0 weeks, though this is Grade 2C evidence 1. The RCOG recommends the same approach as singletons for twins and triplets 2.

Fetal Anomalies

Consider use in pregnancies with fetal anomalies expected to deliver in the late preterm window, though data are limited (Grade 2C) 1.

Imminent Delivery (<12 hours)

Consider giving corticosteroids even if delivery is expected in less than 12 hours, as benefits are seen even with a single dose 1, 2.

Timing Considerations

Optimal benefit occurs when delivery happens 24-48 hours after the first dose and within 7 days 2. However, benefits persist even if delivery occurs within 24 hours of the first dose 2. Do not delay medically indicated delivery to complete the corticosteroid course 2.

Counseling Requirements

You must counsel patients about uncertain long-term risks (Grade 1C) 1. While short-term respiratory benefits are established for the late preterm period, long-term neurodevelopmental outcomes remain incompletely studied. Some evidence suggests potential associations with psychiatric and behavioral diagnoses, though data are limited 2.

Common Pitfalls to Avoid

  1. Do not give corticosteroids "just in case" at term for scheduled cesarean delivery—the evidence does not support this practice in the United States despite some international data 2

  2. Do not give to diabetic mothers in the late preterm period due to hypoglycemia risk 1

  3. Do not give if delivery is unlikely within 7 days—benefits disappear after this window 1, 2

  4. Do not give repeat courses in the late preterm period—only a single course is recommended 1

References

Guideline

antenatal corticosteroids to reduce neonatal morbidity and mortality: green-top guideline no. 74.

BJOG : an international journal of obstetrics and gynaecology, 2022

Research

European guidelines on perinatal care: corticosteroids for women at risk of preterm birth.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.